Document is current
Any future updates will be listed below
-
Authors
Collier, Katharine A. https://orcid.org/0000-0003-0485-8031
Valencia, Hugo
Newton, Herbert https://orcid.org/0000-0003-2291-7568
Hade, Erinn M. https://orcid.org/0000-0001-8977-6443
Sborov, Douglas W. https://orcid.org/0000-0003-4268-2698
Cavaliere, Robert
Poi, Ming https://orcid.org/0000-0001-6065-8662
Phelps, Mitch A. https://orcid.org/0000-0002-1615-5280
Liva, Sophia G. https://orcid.org/0000-0002-3838-5001
Coss, Christopher C. https://orcid.org/0000-0002-8184-9190
Wang, Jiang
Khountham, Soun
Monk, Paul https://orcid.org/0000-0002-0508-2987
Shapiro, Charles L.
Piekarz, Richard https://orcid.org/0000-0002-3591-7893
Hofmeister, Craig C. https://orcid.org/0000-0003-4816-1607
Welling, D. Bradley https://orcid.org/0000-0002-9963-469X
Mortazavi, Amir https://orcid.org/0000-0002-2122-6805
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01129193 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
https://doi.org/10.1007/s00280-020-04229-3
-
Funding
Funding for this research was provided by:
National Cancer Institute of the National Institutes of Health (U01CA076576, R01CA201382)
- License Information
-
More Information
Article History
Received: 31 May 2020
Accepted: 29 December 2020
First Online: 25 January 2021
Compliance with ethical standards
:
: Christopher C. Coss, Sophia G. Liva, and Mitch A. Phelps are listed as inventors on a provisional patent for AR-42 for cancer-related cachexia (U.S. Patent Application No. 62/898,992). Craig C. Hofmeister has received research grants from Takeda and Oncolytics Biotech; research and personal grants from Janssen, BMS, Sanofi, Nektar, Karyopharm, Imbrium and Oncopeptides, all outside the submitted work. D. Bradley Welling is a consultant for CereXis who is a subsidiary of Recursion Pharmaceuticals. Amir Mortazavi is on the advisory board for Seattle Genetics and Pfizer and is on the scientific advisory board for Debiopharm Group. His institution (not him) has received research funding from Acerta Pharma, Genentech, Roche, Merck, Novartis, Seattle Genetics, Astellas Pharma, Mirati Therapeutics, and Bristol-Myers Squibb. The other authors declare no potential conflict of interest. The Ohio State University (OSU) holds the patent on the investigational drug AR-42 (US 10/597,022). The Technology Commercialization Office has licensed AR-42 (now called REC-2282) to Recursion Pharmaceuticals using the institution’s standard terms, conditions and approval process, in which no author participated. To assure absence of institutional conflict of interest in assessment of response and attribution of toxicity, both were reviewed by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) prior to reporting results. Safety issues related to dose increases and attribution of response were monitored by the Ohio State University Data Safety Monitoring Committee and the OSU Cancer Center Institutional Review Board (IRB).
: This study was performed under the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the Ohio State University (Protocol 2010C0006, approval date 3/24/2010).
: Written informed consent was obtained from all patients.
: Not applicable. There is no patient identifying information or image included in this article.
: Not applicable.
